Symptoms

Symptoms

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

In this thirteenth video, the fifth from the afternoon breakout survivorship sessions, GRACE presents Exercise for Lung Cancer Patients, with Jeffrey Eagan DPT.
In this twelfth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fourth video from these sessions is Dealing with Down Days, presented by Jeanice Hansen, MSW, LCSW, OSW-C.
In this eleventh video from the Targeted Therapies in Lung Cancer Patient Forum, the third from the afternoon breakout survivorship sessions, GRACE presents Chemo Brain, with Denise Damek, MD.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Cancer Journey:
Cancer Type:
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
Cancer Journey:
Cancer Type:

Articles

The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.
Cancer Journey:
Cancer Type:
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
Cancer Journey:
Cancer Type:
Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.
Cancer Journey:
Cancer Type:
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.
Cancer Journey:
Cancer Type:
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
Cancer Journey:
Cancer Type:

Community Forum

No Result Found